Revenue grew 1.7% as same-unit pricing and volume each contributed 0.3%.
MD Pediatrix Medical Group, Inc.
XNYS
30.87
−2.37%
Pre-market
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MD
$30.87
▼ -2.37%
What changed
Recent filings, trades and movesKey stats
$31.62
Pre-market
$30.87
-2.37%
- 52-Week Range
- $17.23 – $33.74
- YTD
- +48.52%
- IV Rank (30D)
- 25.24
- Straddle Price
- $3.17
- P/C Vol Ratio
- 2.43
- Market Cap
- $2.5B
- Open
- $31.48
- Day Range
- $30.84 – $31.69
- Volume
- 536,368
- Prev Close
- $31.49
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.86% |
| Beta vs SPY | 0.79 |
| Cost of Equity (CAPM) | 8.79% (VRP-adj) |
| WACC | 8.32% |
| Volatility Risk Premium | +55.1pp (IV − HV30) |
| Effective Tax Rate | 26.2% |
| Rev. Growth (YoY, DCF input) | +1.5% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.02 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | 17.7% |
| Book / Price | 33.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 10.7% |
| Debt / Equity | 0.47 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | -3.2% (reverse-DCF on current price) |
| SMA 50 | $27.61 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $29.53 |
| Bollinger Width / SMA20 | 22.3% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $3B |
Peers used for multiples: COLL, HCSG, HRMY, OSCR, UNH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
48%
20-Day Fair Value
≈ by Dec 10, 2026
$31.44
α -0.6%
rank 44%
conviction
44%
40-Day Fair Value
≈ by Jan 8, 2027
$31.87
α +0.8%
rank 44%
conviction
30%
60-Day Fair Value
≈ by Feb 8, 2027
$31.04
α -1.8%
rank 44%
conviction
48%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $42.63 | 25% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $29.87 | 11% | median 16.0× · 5 peers |
| Peer EV/EBITDA | $24.93 | 11% | median 7.8× · 5 peers |
| Peer P/B | $33.46 | 2% | median 3.1× · 5 peers |
| Peer P/S | $22.21 | 8% | median 0.9× · 5 peers |
| Market Anchor (SMA50) | $27.61 | 43% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $33.96 | 0% | 7 strikes · skew -1.36 |
As of 2026-11-11 · updated
Related
About
- Industry (SIC)
- SERVICES-HOSPITALS (8060) · industry map
- Exchange
- XNYS
- Market Cap
- $2.5B
- Employees
- 2,260
- List Date
- 1959-03-31
- CIK
- 0000893949
- Last Earnings
- Oct 29 before open · +0.9% vs ±16.5% expected
- Next Earnings
- ~Feb 18, 2027 (estimated)
- Headquarters
- Sunrise, FL
- Homepage
- https://www.pediatrix.com
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 14.20% | -11.73% | 2.20% | -0.21% | 7.29% | 0.42% | 2.03% |
| Feb | -13.58% | -3.10% | -0.06% | -4.69% | 6.11% | -7.42% | -3.79% |
| Mar | 3.96% | 2.31% | -3.50% | 14.37% | -0.14% | 9.30% | 4.38% |
| Apr | 3.83% | -22.87% | -3.89% | -8.93% | -11.23% | 8.74% | -5.73% |
| May | 20.82% | 1.58% | -7.19% | -18.87% | 11.07% | -5.32% | 0.35% |
| Jun | -7.06% | 10.23% | 4.79% | 1.75% | 5.98% | 17.16% | 5.48% |
| Jul | -3.99% | 3.14% | -1.51% | 17.30% | -14.52% | 1.14% | 0.26% |
| Aug | 8.15% | -23.02% | 3.44% | 31.64% | 43.66% | -0.08% | 10.63% |
| Sep | -9.80% | -6.72% | -9.02% | 8.72% | -0.77% | -2.80% | -3.40% |
| Oct | -5.19% | 14.66% | -10.54% | 2.67% | -0.18% | 15.76% | 2.86% |
| Nov | -8.36% | -18.22% | -25.25% | -1.64% | 14.28% | 2.96%* | -6.04% |
| Dec | 11.38% | -8.50% | 6.04% | -12.59% | -11.17% | -- | -2.97% |
| Total | 8.42% | -51.98% | -39.45% | 21.18% | 46.68% | 43.50% | 4.73% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $29.53
SMA 50: $27.61
SMA 200: $24.20
Current: $31.62
EMA 12: $30.63
EMA 26: $29.35
MACD: 1.2820 | Signal: 0.1830
BULLISH
ADX (14): 50.22
STRONG TREND
+DI: 35.62
−DI: 9.83
Momentum Oscillators
RSI (14): 68.32
NEUTRAL
Stoch %K: 62.91
Stoch %D: 67.60
Williams %R: -36.93
Volume & Volatility
BB Upper: $32.83
BB Lower: $26.24
NEUTRAL
OBV: 40,827,424
Vol SMA 20: 764,182
Vol ROC: -19.78%
ATR: $1.11
True Range: $0.85
HV 20: 37.6%
HV 30: 32.2%
HV 60: 27.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before MD’s Oct 29 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key drivers:
- Technical indicators suggest a weak trend with a possible reversal in the near term
- Recent news sentiment is generally neutral, with some bearish signals from options activity
Primary risks:
- Continued weakness in the overall market could further pressurize MD's price
- High implied volatility may lead to increased price swings and higher risk for investors
Investment thesis: The stock is likely to experience a period of consolidation or even a reversal in the near term, driven by technical indicators and recent news sentiment. Investors should carefully consider the risks and potential rewards before entering a position.
Recent news sentiment impact: The neutral news sentiment has had a limited impact on the stock price, but the bearish signals from options activity could contribute to further weakness if the market remains under pressure.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - WEAK TREND; Medium-term (1-3 months) - NEUTRAL; Long-term (3-12 months) - BULLISH
Support/Resistance Levels:
- Lower band: $24.77
- Middle band: $26.01
- Upper band: $27.26
- Critical support level: $25.00
Momentum Signals:
- RSI interpretation: NEUTRAL (52.14) - not overbought or oversold
- MACD signal: BULLISH (0.26 / Signal: -0.12 / Histogram: 0.38)
- Bollinger Bands position: NEUTRAL (signal line is flat, indicating a lack of momentum)
Volume Analysis: Volume trends are generally positive, with an increasing volume rate of change and a high OBV reading.
News & Sentiment Analysis
Recent Headlines Summary: The news headlines have been mostly neutral, with some bearish signals from options activity.
Sentiment Assessment: NEUTRAL (average sentiment across all headlines)
Catalyst Identification: No specific catalysts are identified in the recent news headlines.
Market Narrative: The market narrative is generally neutral, with no strong bullish or bearish signals driving the stock price.
Risk & Volatility Assessment
Beta Interpretation: LOW RISK (beta: 0.53) - the stock moves less than the market
Volatility Regime: LOW VOLATILITY (historical volatility: HV20 52.8%, HV30 46.8%) - the stock is less volatile than usual
Options Market Signals: IV rank: 10.5% (LOW); Put/call ratio: 3.33 (BEARISH)
Downside Protection: Support levels are relatively strong, with a critical support level at $25.00.
Market Context & Positioning
Sector Performance: MD's sector is performing relatively well, with a positive R-squared correlation to the market.
Institutional Activity: Institutional interest is moderate, with an increasing volume rate of change and a high OBV reading.
Correlation Analysis: The stock has a low correlation to the market (R-squared: 0.16), indicating that it may not be highly influenced by broader market trends.
Relative Valuation: MD's relative valuation is neutral, with no strong buy or sell signals from technical indicators.
Key Levels & Action Items
Critical Price Levels:
- Lower band: $24.77
- Middle band: $26.01
- Upper band: $27.26
- Critical support level: $25.00
Breakout/Breakdown Levels: No specific levels are identified for breakout or breakdowns.
Time-Sensitive Catalysts: No specific catalysts are identified in the recent news headlines.
Risk Management: Stop-loss levels should be set at $24.77, with a position sizing consideration of 2-3% of total portfolio value.
Please let me know if you would like me to revise or expand on this analysis.
Generated
News
All MD news →
Earnings History
20 of 23 under expected move
Avg Expected Move
16.78%
Avg Actual Move
5.75%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-18 | After-Close | 6.96% | 5.67% | 0.81x | Within |
| 2021-05-07 | After-Close | 10.03% | 0.37% | 0.04x | Within |
| 2021-08-06 | After-Close | 18.32% | 1.27% | 0.07x | Within |
| 2021-10-28 | After-Close | 12.60% | 1.94% | 0.15x | Within |
| 2022-02-17 | After-Close | 5.17% | 3.31% | 0.64x | Within |
| 2022-04-28 | After-Close | 12.32% | 10.49% | 0.85x | Within |
| 2022-11-03 | After-Close | 19.76% | 2.83% | 0.14x | Within |
| 2023-02-17 | After-Close | 12.87% | 5.63% | 0.44x | Within |
| 2023-05-02 | After-Close | 11.40% | 5.16% | 0.45x | Within |
| 2023-08-03 | After-Close | 15.82% | 0.68% | 0.04x | Within |
| 2023-11-02 | After-Close | 19.21% | 0.10% | 0.01x | Within |
| 2024-02-20 | After-Close | 13.95% | 2.36% | 0.17x | Within |
| 2024-05-07 | After-Close | 35.91% | 6.08% | 0.17x | Within |
| 2024-08-06 | After-Close | 85.84% | 7.36% | 0.09x | Within |
| 2024-11-01 | Pre-Market | 12.58% | 23.46% | 1.86x | Exceeded |
| 2025-01-13 | After-Close | 9.20% | 2.63% | 0.29x | Within |
| 2025-05-06 | After-Close | 7.94% | 0.90% | 0.11x | Within |
| 2025-08-05 | After-Close | 7.74% | 11.76% | 1.52x | Exceeded |
| 2025-11-03 | Pre-Market | 14.88% | 24.22% | 1.63x | Exceeded |
| 2026-02-19 | After-Close | 8.29% | 2.49% | 0.30x | Within |
| 2026-05-05 | After-Close | 12.84% | 6.63% | 0.52x | Within |
| 2026-08-04 | Pre-Market | 15.81% | 5.87% | 0.37x | Within |
| 2026-10-29 | Pre-Market | 16.52% | 0.93% | 0.06x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MD Options Activity & IV Rank
MD IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 39.0%
7-DTE IV: 51.0%
Expected Move: $3.17
7-DTE Move: $2.20
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 103
Put Volume: 250
P/C Volume: 2.427
BEARISH
Call OI: 423
Put OI: 313
P/C OI: 0.74
Total OI: 736
ATM Options Pricing
ATM Call: $2.15
ATM Put: $1.02
Call %: 6.8%
Put %: 3.2%
Chain Summary
Chain Volume: 353
Chain OI: 736
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 79th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
79%
vs own history
GEX tilt
+0.38
OI-weighted, today
Vanna tilt
+0.20
δ-sensitivity to IV
Charm tilt
-0.32
δ-decay vs time
Charm tilt -0.32: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)11.7LowNov 10
IV Rank (30 DTE)25.2MediumNov 10
Straddle Price (30 DTE)$3.17Nov 10
Beta Analysis
Risk Metrics
Beta: 0.3535
Alpha: 36.36%
Correlation: 0.1375
R-Squared: 1.9%
Stock Volatility: 35.2%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own MD
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Rockefeller Capital Management Family office Rockefeller family | $33.9M | #325 of 4729 | +75.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $32.6M | #498 of 3138 | -16.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.4M | #2764 of 3716 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MD Institutional Ownership (13F)
Filings for 2026-06-30 · 130 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 82,179,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$552.19K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $552.19K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
MD Insider Trading (Form 4)
Latest: 2026-09-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Laura A Linynsky | Director | Disp (D) | −6,000 | $26.82 | -$160.9K | EDGAR |
| 2026-08-18 | Sylvia Jean Young | Director | Disp (D) | −18,500 | $26.62 | -$492.5K | EDGAR |
| 2026-08-14 | Laura A Linynsky | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Michael A. Rucker | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Sylvia Jean Young | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Kurt Douglas Newman | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Guy P Sansone | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Shirley A Weis | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | Thomas McEachin | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-08-14 | John M. Starcher Jr. | Director | Award (A) | +472 | $26.50 | $12.5K | EDGAR |
| 2026-06-24 | David Haddock | EVP, GC & Corp Sec | Award (A) | +20,036 | — | EDGAR | |
| 2026-06-10 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | Gift (G) | — | — | EDGAR | |
| 2026-06-03 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | Tax (F) | −11,944 | $21.54 | -$257.3K | EDGAR |
| 2026-06-03 | Kasandra H Rossi | EVP, CFO and Treasurer | Mixed Tax −3,701 · Grant +31,800 |
+28,099 | $21.54 | -$79.7K | EDGAR |
| 2026-06-03 | Mark S Ordan | Chief Executive Officer | Mixed Tax −19,119 · Grant +224,372 · Disp −97,174 |
+108,079 | $21.54 | -$411.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MD Insider Holdings
13 insiders · @ $31.62
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mark S Ordan | Chief Executive Officer | 410,884 | $12.99M | -$5.05M | 15 | 2026-06-03 |
| 2 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | 189,890 | $6.00M | -$150.1K | 14 | 2026-06-10 |
| 3 | Don Gregory Neeb | EVP, Chief Invest & Strategy | 145,234 | $4.59M | $0 | 2 | 2026-06-03 |
| 4 | Kasandra H Rossi | EVP, CFO and Treasurer | 105,100 | $3.32M | $0 | 5 | 2026-06-03 |
| 5 | Guy P Sansone | Director | 87,416 | $2.76M | $0 | 8 | 2026-08-14 |
| 6 | Thomas McEachin | Director | 73,741 | $2.33M | $0 | 10 | 2026-08-14 |
| 7 | John M. Starcher Jr. | Director | 73,732 | $2.33M | $0 | 8 | 2026-08-14 |
| 8 | Michael A. Rucker | Director | 66,769 | $2.11M | -$241.0K | 9 | 2026-08-14 |
| 9 | Laura A Linynsky | Director | 33,900 | $1.07M | -$294.6K | 9 | 2026-09-14 |
| 10 | Sylvia Jean Young | Director | 29,786 | $941.8K | $0 | 6 | 2026-08-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MD Board & Officers
As of SEC filings through Sep 14, 2026Directors 9
- Michael A. Rucker · since May 16, 2019
- Guy P Sansone · since Jul 12, 2020
- John M. Starcher Jr. · since Jul 12, 2020
- Mark S Ordan · since Jul 12, 2020
- Shirley A Weis · since Jul 12, 2020
- Thomas McEachin · since Jul 12, 2020
- Laura A Linynsky · since May 12, 2022
- Sylvia Jean Young · since May 12, 2023
- Kurt Douglas Newman · since Jul 1, 2025
Officers 5
- Mark S Ordan · Chief Executive Officer · listed since Jan 2025
- Kasandra H Rossi · EVP, CFO and Treasurer · since Oct 1, 2024
- Mary Ann E Moore · EVP, GC, Chief Admin Off & Sec · listed since Nov 2024
- Don Gregory Neeb · EVP, Chief Invest & Strategy · since Aug 1, 2025
- David Haddock · EVP, GC & Corp Sec · since Jun 22, 2026
Changes in the last 10 years (40)
| Jun 22, 2026 | David Haddock became EVP, GC & Corp Sec |
| Aug 1, 2025 | Don Gregory Neeb became EVP, Chief Invest & Strategy |
| Jul 1, 2025 | Kurt Douglas Newman became a director |
| Jan 14, 2025 | Mark S Ordan first listed as Chief Executive Officer in an SEC filing |
| Nov 12, 2024 | Mary Ann E Moore listed as EVP, GC, Chief Admin Off & Sec (previously EVP, General Counsel & Sec) in SEC filings |
| Oct 1, 2024 | Kasandra H Rossi became EVP, CFO and Treasurer |
| Aug 1, 2024 | The company announced the departure of Curtis Pickert as EVP, Chief Operating Officer in an SEC filing |
| Jun 17, 2024 | The company announced the departure of Lee Wood as EVP, Natl & Market Operations in an SEC filing |
| Jun 16, 2023 | James D Swift first listed as a director in an SEC filing |
| May 15, 2023 | Mark S Ordan no longer listed as Chief Executive Officer in SEC filings |
| May 12, 2023 | Sylvia Jean Young became a director |
| Mar 8, 2023 | The company announced the departure of Roger Md Medel from the board in an SEC filing |
| Mar 8, 2023 | The company announced the departure of Roger Md Medel from the board in an SEC filing |
| Mar 8, 2023 | The company announced the departure of Roger Md Medel from the board in an SEC filing |
| Mar 3, 2023 | Mary Ann E Moore listed as EVP, General Counsel & Sec (previously EVP Chief ERM/Legal Ops Off) in SEC filings |
| Mar 3, 2023 | James D Swift listed as Chief Executive Officer (previously EVP, Chief Operating Officer) in SEC filings |
| Feb 13, 2023 | Lee Wood became EVP, Natl & Market Operations |
| Feb 13, 2023 | Curtis Pickert became EVP, Chief Operating Officer |
| Nov 9, 2022 | James D Swift first on file as EVP, Chief Operating Officer |
| Sep 19, 2022 | The company announced the departure of Dominic J Andreano as EVP, General Counsel and Secy in an SEC filing |
| May 12, 2022 | Laura A Linynsky became a director |
| Nov 16, 2021 | Mary Ann E Moore became EVP Chief ERM/Legal Ops Off |
| Dec 11, 2020 | Roger Md Medel no longer listed as Chief Executive Officer in SEC filings |
| Oct 2, 2020 | Stephen D Farber reported in an SEC filing no longer being Chief Financial Officer |
| Oct 1, 2020 | C Marc Richards became EVP, Chief Financial Officer |
| Sep 27, 2020 | Roger Mack Hinson became Pres., PDX & OBX Medical Group |
| Jul 12, 2020 | Thomas McEachin became a director |
| Jul 12, 2020 | Shirley A Weis became a director |
| Jul 12, 2020 | Mark S Ordan became a director |
| Jul 12, 2020 | Mark S Ordan became Chief Executive Officer |
| Jul 12, 2020 | John M. Starcher Jr. became a director |
| Jul 12, 2020 | Guy P Sansone became a director |
| Feb 18, 2020 | Dominic J Andreano listed as EVP, General Counsel and Secy (previously SVP, General Counsel and Secy) in SEC filings |
| Feb 13, 2020 | Nicholas J Nikolopoulos became EVP Chf Strategy & Growth Offi |
| May 16, 2019 | Michael A. Rucker became a director |
| May 16, 2019 | Carlos A Migoya became a director |
| Feb 14, 2019 | Joseph M Calabro listed as President (previously President and COO) in SEC filings |
| Feb 14, 2019 | David A. Clark listed as Chief Operating Officer (previously Pres. Mednax Natl Med Group) in SEC filings |
| Nov 6, 2018 | Stephen D Farber became Chief Financial Officer |
| Jun 2, 2017 | David A. Clark listed as Pres. Mednax Natl Med Group (previously COO, Pediatrix Medical Group) in SEC filings |
Not reported recently (18)
- James D Swift · Last reported as Chief Executive Officer in an SEC filing dated Sep 3, 2024
- C Marc Richards · Last reported as EVP, Chief Financial Officer in an SEC filing dated Aug 13, 2024
- Roger Mack Hinson · Last reported as Pres., PDX & OBX Medical Group in an SEC filing dated Mar 3, 2022
- John C Pepia · Last reported as Principal Accounting Officer in an SEC filing dated Nov 10, 2021
- Paul G Gabos · Last reported as a director in an SEC filing dated May 14, 2021
- Md Carlo A Waldemar · Last reported as a director in an SEC filing dated May 14, 2021
- Manuel Kadre · Last reported as a director in an SEC filing dated May 14, 2021
- Karey D Barker · Last reported as a director in an SEC filing dated May 14, 2021
- Nicholas J Nikolopoulos · Last reported as EVP Chf Strategy & Growth Offi in an SEC filing dated Sep 17, 2020
- MD Pascal J Goldschmidt · Last reported as a director in an SEC filing dated Feb 18, 2020
- Michael Fernandez · Last reported as a director in an SEC filing dated Feb 18, 2020
- Enrique Sosa · Last reported as a director in an SEC filing dated Feb 18, 2020
- Cesar L Alvarez · Last reported as a director in an SEC filing dated Feb 18, 2020
- Carlos A Migoya · Last reported as a director in an SEC filing dated Feb 18, 2020
- David A. Clark · Last reported as Chief Operating Officer in an SEC filing dated Dec 3, 2019
- Joseph M Calabro · Last reported as President in an SEC filing dated Jun 4, 2019
- Vivian Lopez-Blanco · Last reported as Chief Financial Officer in an SEC filing dated Jun 13, 2018
- Donna E Shalala · Last reported as a director in an SEC filing dated Mar 2, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MD Proposed Insider Sales (Form 144)
Latest: 2026-09-14
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $1.5M notice value
· 3 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Mary Ann E Moore (2, $819K) · Sylvia Young (1, $492K) · Laura Linynsky (1, $161K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 | Mary Ann E Moore | Officer | 21,335 | $572.6K | 2026-09-11 | Merrill Lynch | — | EDGAR |
| 2026-09-14 | Mary Ann E Moore | Officer | 9,260 | $246.4K | 2026-08-14 | Merrill Lynch | — | EDGAR |
| 2026-09-10 | Laura Linynsky | Director | 6,000 | $160.7K | 2026-09-10 | Merrill Lynch | — | EDGAR |
| 2026-08-14 | Sylvia Young | Director | 18,500 | $491.9K | 2026-08-14 | Merrill Lynch | — | EDGAR |
| 2026-05-13 | Weis Shirley A | Director | 36,028 | $853.1K | 2026-05-13 | Robert W. Baird & Co. | — | EDGAR |
| 2025-12-15 | ORDAN MARK S | Director | 23,000 | $517.5K | 2025-12-15 | Piper Sandler & Co Inc | — | EDGAR |
| 2025-11-17 | Rucker Michael A. | Director | 10,478 | $241.0K | 2025-11-17 | Robert W. Baird | — | EDGAR |
| 2025-11-06 | Laura A Linynsky | Director | 10,000 | $216.2K | 2025-11-06 | Merrill Lynch | — | EDGAR |
| 2025-02-21 | Swift James D | Former Officer | 18,530 | $308.1K | 2025-02-21 | Merrill Lynch | — | EDGAR |
| 2024-11-13 | ORDAN MARK S | Director | 27,600 | $427.8K | 2024-11-13 | Piper Sandler & Co Inc | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
119 ETFs hold MD
25 shown · $680.69M total exposure · 0.13% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.14% | $151.1M | $106.3B | 2026-11-09 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.09% | $68.1M | $77.8B | 2026-11-09 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $67.8M | — | 2026-09-30 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $47.1M | — | 2026-09-30 |
| 5 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.11% | $36.1M | — | 2026-11-09 |
| 6 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.05% | $30.6M | — | 2026-09-30 |
| 7 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.10% | $26.5M | — | 2026-11-09 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.17% | $24.6M | $14.1B | 2026-11-09 |
| 9 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $23.0M | — | 2026-09-30 |
| 10 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.14% | $22.8M | $16.1B | 2026-11-09 |
| 11 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.30% | $22.6M | $7.5B | 2026-11-09 |
| 12 | XSMO Invesco S&P SmallCap Momentum ETF | Invesco | 0.73% | $20.1M | — | 2026-11-09 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.06% | $19.7M | — | 2026-11-09 |
| 14 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.30% | $14.3M | $4.7B | 2026-11-09 |
| 15 | RSMC Rockefeller U.S. Small-Mid Cap ETF | Nport | 1.68% | $12.8M | — | 2026-07-31 |
| 16 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $12.3M | — | 2026-09-30 |
| 17 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $11.6M | — | 2026-11-09 |
| 18 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.45% | $10.7M | — | 2026-06-30 |
| 19 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.11% | $10.3M | — | 2026-08-31 |
| 20 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $10.0M | — | 2026-08-31 |
| 21 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.13% | $9.8M | — | 2026-11-09 |
| 22 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.25% | $9.1M | — | 2026-07-31 |
| 23 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.12% | $7.2M | — | 2026-09-30 |
| 24 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.5M | — | 2026-09-30 |
| 25 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.18% | $6.0M | $3.2B | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$1.84
TTM Revenue
$1.96B
TTM Net Income
$150.09M
TTM Op. Cash Flow
$226.88M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $501.37M | $46.99M | $0.59 | $117.31M |
| Q2 '26 | 2026-06-30 | $487.78M | $39.84M | $0.49 | $125.32M |
| Q1 '26 | 2026-03-31 | $476.20M | $29.57M | $0.36 | $-129.85M |
| Q4 '25 | 2025-12-31 | $493.77M | $33.68M | $0.40 | $114.10M |
| Q3 '25 | 2025-09-30 | $492.88M | $71.71M | $0.84 | $137.28M |
| Q2 '25 | 2025-06-30 | $468.84M | $39.26M | $0.46 | $137.17M |
| Q1 '25 | 2025-03-31 | $458.36M | $20.74M | $0.24 | $-117.46M |
| Q4 '24 | 2024-12-31 | $502.36M | $30.48M | $0.37 | $133.01M |
| Q3 '24 | 2024-09-30 | $511.16M | $19.44M | $0.23 | $91.84M |
| Q2 '24 | 2024-06-30 | $504.30M | $-153.03M | $-1.84 | $106.95M |
| Q1 '24 | 2024-03-31 | $495.10M | $4.04M | $0.05 | $-125.23M |
| Q4 '23 | 2023-12-31 | $496.44M | $-124.29M | $-1.50 | $69.25M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
15.13
P/B
3.01
P/S
1.36
EV/EBITDA
10.47
EV/Sales
1.42
ROE
19.8%
ROA
8.2%
Div Yield
0.00%
FCF Yield
9.31%
Debt/Equity
0.45
Current Ratio
—
Market Cap
$2.65B
as of 2026-11-10
MD vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $356.3B | 30.6 | +9.7% | +20.4% | 46 |
| OSCR Oscar Health, Inc. | $10.0B | — | +32.3% | +123.6% | 0 |
| PTGX Protagonist Therapeutics, Inc | $8.9B | 133.6 | +34.8% | +56.3% | 0 |
| RDNT RadNet, Inc. Common Stock | $6.2B | — | +18.9% | +9.9% | 25 |
| PGNY Progyny, Inc. Common Stock | $2.6B | 33.4 | +5.5% | +41.5% | 19 |
| MD Pediatrix Medical Group, Inc. | $2.5B | 17.2 | +1.9% | +48.5% | 25 |
| HRMY Harmony Biosciences Holdings, Inc. Commo | $2.0B | 11.1 | +19.8% | −10.2% | 33 |
| HCSG Healthcare Services Group | $1.7B | 17.1 | +4.0% | +45.8% | 20 |
| COLL Collegium Pharmaceutical, Inc. Common St | $768M | 19.9 | +14.3% | −46.3% | 40 |
| Peer median | $4.4B | 25.2 | +16.6% | +31.0% | 22 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.37M
SI % of Float
5.52%
Days to Cover
5.83
Short Vol Ratio
51.6%
Free Float
79.22M
Float %
97.5%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-24